United Kingdom · Taylor & Francis

lock Subscription

HIV Clinical Trials

HIV Clinical Trials is a journal indexed in SJR in Infectious Diseases and Pharmacology (medical) with an H index of . It has a price of 2395 €. It is published in English.

ISSN: 1528-4336

Publisher: Taylor & Francis

Category: Infectious Diseases

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

NPD

H-index NPD

Acceptance rate pie_chart

NPD

Source NPD

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

2.395 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

SJR Impact

—

H-index

—

Docs (year)

—

Docs 3y

—

Total refs

—

Cites 3y

—

Citable 3y

—

Cites/Doc 2y

—

Ref/Doc

—

Immediate OA

2395 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Atazanavir: The Advent of a New Generation of More Convenient Protease Inhibitors

World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects Revised October 7, 2000

Effect of HAART on Health Status and Hospital Costs of Severe HIV-Infected Patients: A Modeling Approach

DHHS Issues Adult Guideline Revisions

Determinants of Sustained Virological Suppression in Indigent, HIV-Infected Patients: Is Single Protease Inhibitor-Based Antiretroviral Therapy Truly Highly Active?

Coronary Heart Disease Risk, Dyslipidemia, and Management in HIV-Infected Persons

Comparison of Neuropsychiatric Side Effects in an Observational Cohort of Efavirenz- and Protease Inhibitor-Treated Patients

Comparative Efficacy of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Combination with Efavirenz: Results of a Systematic Overview

Combination Therapy with Indinavir, Ritonavir, and Delavirdine and Nucleoside Reverse Transcriptase Inhibitors in Patients with HIV/AIDS Who Have Failed Multiple Antiretroviral Combinations

Combination Therapy With Hydroxyurea Versus Without Hydroxyurea As First Line Treatment Options for Antiretroviral-Naive Patients

Clinical Utility of Monitoring Serum Cryptococcal Antigen (sCRAG) Titers in Patients with AIDS-Related Cryptococcal Disease

Benfluorex As a Therapeutic Option for Insulin Resistance in HIV Lipodystrophy Syndrome

SHOW MORE ARTICLES

Bacterial Infections in Adult HIV-Infected Patients

2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus July 2001: DRAFT

Atazanavir Plasma Concentrations Vary Significantly Between Patients and Correlate with Increased Serum Bilirubin Concentrations

Assessment of readiness to initiate antiretroviral therapy

Antiviral Potency of HAART Regimens and Clinical Success Are Not Strictly Coupled in Real Life Conditions: Evidence from the MASTER-1 Study

Antiretroviral Treatments to Reduce Mother-to-Child Transmission of HIV

Adherence to Antiretroviral Therapy: Appropriate Use of Self-Reporting in Clinical Practice

Adherence and HIV Drug Resistance

A Randomized Trial of Nelfinavir, Ritonavir, or Delavirdine in Combination with Saquinavir-SGC and Stavudine in Treatment-Experienced HIV-1-Infected Patients

A Randomized Controlled Trial of the Clinical Utility of Genotypic Resistance Testing in Patients with Limited Prior Exposure to Antiretroviral Drugs

A Practical Guide to Applying the Intention-to-Treat Principle to Clinical Trials in HIV Infection

A Decade Surveillance Study ofMycobacterium xenopiDisease and Antimicrobial Susceptibility Levels in a Reference Teaching Hospital of Northern Italy: HIV-Associated Versus Non-HIV-Associated Infection

FAQs

SJR is not available (NPD) for HIV Clinical Trials in the CountryOfPapers database.

Immediate OA APC is 2395 EUR. Non-OA / submission fee is 0 EUR.